Author

G. Batist

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Research Focus:differential expression· 2 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:clustering· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1 Assay:proteomics· 1

Frequent Co-Authors

A. A. N. Rose· 1 shared A. Aguilar-Mahecha· 1 shared A. G. Waks· 1 shared A. Spreafico· 1 shared C. H. Borchers· 1 shared C. P. Yu· 1 shared D. Kim· 1 shared D. W. Cescon· 1 shared

Activity by Year

2019-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 13 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. A. N. Rose

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

The clinical, genomic, and transcriptomic landscape of BRAF mutant cancers

S. Kazandjian, E. Rousselle, M. Dankner, D. W. Cescon, A. Spreafico, K. Ma, P. Kavan, G. Batist, A. A. N. Rose

This paper analyzes the clinical, genomic, and transcriptomic features of BRAF mutant cancers across multiple tumor types and identifies demographic and molecular differences between BRAF mutation classes.

bioRxiv · Sep 15, 2023Cancer Biology

Clinical proteomics reveals vulnerabilities in non-invasive breast ductal carcinoma and drives personalized treatment strategies.

G. Mitsa, L. Florianova, J. Lafleur, A. Aguilar-Mahecha, R. P. Zahedi, S. V. Del Rincon, M. Basik, C. H. Borchers, G. Batist

The paper uses clinical proteomics to identify biomarkers and metabolic vulnerabilities in DCIS, informing therapeutic strategies and developing a targeted proteomics assay for cancer-related pathways.

bioRxiv · Jul 11, 2023 · PreprintCancer Biology

The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancer

S. A. Wander, O. Cohen, X. Gong, G. N. Johnson, J. Buendia-Buendia, M. R. Lloyd, D. Kim, F. Luo, P. Mao, K. Helvie, K. J. Kowalski, U. Nayar, A. G. Waks, S. Parsons, R. Martinez, , N. Wagle

The paper identifies eight resistance mechanisms to CDK4/6 inhibitors in HR+ breast cancer, present in 80% of resistant tumors, with potential therapeutic strategies.

bioRxiv · Nov 28, 2019Cancer Biology